CONCLUSIONS:
The proposed minimal quality specifications based on biological variation are generally slightly less stringent than those currently in use, although they do not drastically change the performance evaluation in the different schemes. These specifications are a first step in the harmonization of practices among the schemes and remain to be evaluated.
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The trace elements copper (Cu), zinc (Zn), and selenium (Se) are essential for life but can also be toxic in humans (1 ) . As components of proteins, enzymes, and hormones, they regulate biological functions, particularly redox balance and inflammatory and immune responses. Pathological disorders such as infections, cancers, and cardiovascular and neurological diseases may be seen when their homeostasis is modified (2) (3) (4) (5) (6) (7) (8) (9) , and interactions between essential and toxic minerals may have some role in determining the susceptibility of individuals to disease (10 ) . Genetic disorders of Cu and Zn transport are known to have profound clinical consequences (5, 11 ) .
Serum concentrations of Cu, Zn, or Se provide useful information in the clinical categorization of deficiency and toxicity states. Serum selenium values Ͻ0.25 mol/L, reported in China (Keshan province), correspond to severe selenium deficiency. Concentrations around 1.25 mol/L provide for optimal glutathione peroxidase activity, whereas concentrations Ͼ1.50 mol/L afford protection against at least some cancers (9, 12 ) . Toxic values (Ͼ4 mol/L) have been found in Venezuela and China (13 ) . Serum zinc values Ͻ6 mol/L are associated with severe zinc deficiencies, whereas zinc concentrations generally fall within the range 12-17 mol/L in healthy adults and values Ͼ25 mol/L are infrequent in clinical practice even after long-term zinc supplementation (5, 6, 14 -16 ) . Serum copper concentrations fall within the range 13-22 mol/L in healthy adults and increase up to 40 mol/L in inflammation (14, 15 ) . Therefore, accurate determinations in plasma or serum are crucial for the diagnosis and follow-up of patients suffering from various diseases (5-9, 11, 17, 18 ) .
Imprecision, bias, and uncertainty in the measured concentrations of serum Cu, Zn, or Se are related to the analytical methods and more generally to the expertise of individual laboratories. The most commonly reported methods for Cu and Zn determination are colorimetry, flame atomic absorption spectrometry (FAAS), 11 inductively coupled plasma atomic/optical emission spectrometry (ICP-AES/OES), electrothermal atomic absorption spectrometry (ETAAS), and inductively coupled plasma-mass spectrometry (ICP-MS), whereas for Se, ETAAS and ICP-MS are the most commonly used methods.
Trace element external quality assessment schemes (TE-EQASs) are used in addition to internal quality control as tools for monitoring laboratory performance. However, preparation of samples, monitoring of participant performance, and the associated assessment of competence, vary between the TE-EQASs (19 -21 ) , a problem that can lead to conflicting conclusions.
The aims of the present work were to use European and North American TE-EQAS results to
• evaluate analytical quality specifications (QSs) based on human biological intra-and interindividual variability from published data for monitoring the performance of laboratories measuring Cu, Zn, and Se in serum or plasma;
• compare these QSs with those currently used by existing quality assessment schemes; and
• use the proposed QS to evaluate the reliability of the most commonly used methods.
Materials and Methods
As a database for this study, we used 
CALCULATION OF THE PROPOSED QUALITY SPECIFICATIONS
We defined QSs for each of the 3 assays as proposed by Fraser (24 ) , using the few studies that reported human biological intra-and interindividual variability of serum or plasma Cu, Zn, and Se (Fig. 2) . We used the average data to calculate optimal, desirable, and minimal QS (19, 24 ) . The QSs were applied to the following formula to calculate z scores:
where x i refers to the participant's result and X to the target value. The QS was divided by 2 to be consistent with the International Organization for Standardization (ISO) guide, which states that performance is satisfactory when the absolute value (Abs) of the z score is Ͻ2 (25 ) .
Our previous work with assays for aluminum in serum and lead in whole blood showed that the QSs need to be modified at low concentrations, when analytical imprecision increases rapidly (19, 24 ) . The threshold concentrations, at which the modification should be introduced, were found by further analysis of those data sets with low concentrations of Cu (Ͻ10 mol/L), Se (Ͻ0.75 mol/L) (9, 26 ) , or Zn (10.7 mol/L) (27 ) . For each of these TE-EQAS samples, we calculated z scores for all of the reported results in 2 ways, by using a) the minimal QS and b) the minimal QS found at the concentrations used to indicate a low value (i.e., 1.2 mol/L at 10 mol/L for Cu, 0.09 mol/L at 0.75 mol/L for Se, and 1.6 mol/L at 10.7 mol/L for Zn).
DATA
We used results reported by participants in each of the 8 schemes during a period of 3 consecutive years in this analysis. Participant values were obtained for plasma or serum samples with very low (around 3.5 mol/L for Cu and 0.25 mol/L for Se), low (9 mol/L for Cu, 8 mol/L for Zn, and 0.50 mol/L for Se), median (15 and 20 mol/L for Cu and Zn and 1.00 and 1.50 mol/L for Se) and high (30 mol/L for Cu and 3.00 mol/L for Se) concentrations. We chose these concentrations to cover physiological and pathological ranges of values (9, 12, 14 -16, 26 -28 ) . For results associated with each set of target values, SD and CV were determined after elimination of outliers at Ϯ3 SD. Participant values reported with qualifiers such as "less than" or "greater than" were also eliminated. These data sets were used to compare performance assessments determined from the QSs currently employed by the schemes and by the proposed QSs.
We also calculated z scores using 3 additional samples (1 native pool of human serum and 2 human serum pools spiked with known Cu, Zn, and Se concentrations), sent to all participants in each of the TE-EQAS for other purposes (29 ) , to provide comparisons of the analytical methods used. For this analysis, the analytical methods used by at least 15 participants were considered (30 ) .
STATISTICS
We used Kruskal-Wallis (or Mann-Whitney) test to compare z scores according to a) target concentrations and b) analytical methods, and Friedman tests and Spearman correlation coefficients for comparing z scores using the various QSs. We calculated simple linear regressions to evaluate the relationships between a) scheme SD and target values and b) scheme SD and QS.
Results

CALCULATION OF QS USING BIOLOGICAL VARIABILITY
Optimal, desirable, and minimal QSs for total error according to the Fraser formulae (19, 24 ) are shown in Table 1 . Results are expressed as the mean (points) and 95% CI (error bars) of the CV% reported in the literature (36 -39 ) . Inter, interindividual variability; Intra, intraindividual variability; P, plasma; S, serum.
With decreasing target concentrations, the percentages of z scores with absolute values, abs(z scores) Ͼ2 found using the 2 calculations described above, remained similar down to threshold concentrations of 7 mol/L for Cu, 8 mol/L for Zn, and 0.6 mol/L for Se. Below these thresholds a fixed concentration was taken for the QS. Therefore, the proposed minimal QSs are
• Cu in serum Ϯ0.84 mol/L or Ϯ12%, whichever is greater;
• Zn in serum Ϯ1.20 mol/L or Ϯ15%, whichever is greater; and
• Se in serum Ϯ0.072 mol/L or Ϯ12%, whichever is greater.
COMPARISON OF EACH QS CURRENTLY USED BY THE VARIOUS TE-EQASs AND THE PROPOSED QS
The acceptable limits currently used for assessing laboratory performance in the various TE-EQASs are indicated in Fig. 1 . Fig. 1 shows that BE and UK use the tightest tolerances for Cu and Zn at normal and high concentrations, whereas NY and the proposed minimal QS give the greatest tolerances. At the threshold values, most of the QSs are very similar for Cu and Zn. For Se, limits used by the NY TE-EQAS are greater than the minimal QS proposed herein, and the latter are greater than those used by the BE, CA, FR, IT, and UK TE-EQASs.
COMPARISON OF LABORATORY PERFORMANCE AND EACH
TE-EQAS QS
A comparison analysis of target values and their SDs for all samples distributed for the various TE-EQASs during 3 consecutive years indicated that imprecision was significantly related to target concentrations for the 3 elements. Correlation coefficients were statistically significant for the 3 elements (r Ͼ 0.56, n ϭ 279, P Ͻ 0.0001). The linear equations between SD and target values (X) were
• for Cu, SD ϭ 0.06X ϩ 0.49;
• for Zn, SD ϭ 0.06X ϩ 0.87; and
• for Se, SD ϭ 0.09X ϩ 0.07.
We compared these equations relating SD to target values with those defining the relationships between QS and trace element concentration (Fig. 1) . For Se, the observed slope was higher than those calculated with the QSs of the IT, BE, CA, FR, and UK schemes and lower than those proposed by NY and by the Network. The ordinate depicting the linear relationship between SDs and target values was similar to those proposed by BE, CA, FR, IT and UK TE-EQAS as well as the fixed limit proposed by the network "Organisers of External Quality Assessment/Proficiency Testing Schemes Related to Occupational and Environmental Medicine." For Zn and Cu, the slopes of the lines defining the relationship between SD and target value were higher than those of the BE and UK TE-EQASs but lower than those of other schemes. For Zn, the ordinate of this line was similar to those of the BE and UK TE-EQASs, and for Cu, the ordinate was similar to those of the CA and FR TE-EQASs.
We also calculated the relationships between SD value and target concentration for the reference laboratories, although the number of samples was limited to the 25 samples from the DE and NY TE-EQASs. The equations were
• Cu, SD ϭ 0.05X Ϫ 0.11 (r ϭ 0.80, n ϭ 25, P Ͻ 0.0001);
• Zn, SD ϭ 0.065X Ϫ 0.13 (r ϭ 0.91, n ϭ 25, P Ͻ 0.0001); and
• Se, SD ϭ 0.045X ϩ 0.03 (r ϭ 0.80, n ϭ 25, P Ͻ 0.0001).
For Se and to a lesser extent for Cu, the slopes of these relationships were found to be lower in the reference laboratories than the participant laboratories, but this was not the case for Zn. Although various methods were used across these laboratories, including FAAS, ICP-AES/OES, ETAAS, and ICP-MS, the differences between the reference laboratories and participant laboratories were not related to analytical method. In addition, the ordinates of the lines depicting the relationships between SDs and target values for the reference laboratories were lower than those obtained with the participant laboratories.
INDIVIDUAL PERFORMANCES EVALUATED USING EACH QS
Each of the participants' results was used to determine a z score according to the QS associated with each dif- 1/2 ϩ z(0.5CV intra ), where CV intra ϭ intraindividual variability, CV inter ϭ interindividual variability, and z ϭ 1.65 for a 95% probability level. Optimal ϭ 0.5 desirable; minimal ϭ 1.5 desirable.
ferent scheme (Fig. 1 ) and the proposed minimal QS. For each set of scores, those at the 10th, 50th, and 90th percentiles are recorded in Table 2 according to concentration and QS. Spearman correlation coefficients between z scores obtained using the various QSs (Cons/NY, Cons/IT, Cons/CA-FR, Cons/UK-BE, NY/IT, NY/CA-FR, NY/UK-BE, IT/CA-FR, IT/ UK-BE, CA-FR/UK-BE) were highly significant (r Ͼ 0.989, n ϭ 801, P Ͻ 0.0001 for Cu; r Ͼ 0.991, n ϭ 528, P Ͻ 0.0001 for Zn; r Ͼ 0.981, n ϭ 505, P Ͻ 0.0001 for Se). No statistically significant difference was observed in the average value of z scores according to target concentration as indicated by the Kruskal-Wallis test, regardless of what QS was used in performing this analysis (P Ͼ 0.79 for Zn, P Ͼ 0.10 for Cu, P Ͼ 0.24 for Se). In addition, the z score values obtained using the various QSs were similar as indicated by the Friedman test (P ϭ 0.12 for Cu, P ϭ 0.96 for Zn, P ϭ 0.41 for Se). When this analysis was performed at each concentration, however, the NY QS was significantly more stringent than the others (P Ͻ 0.0001) ( Table 2 ) at a very low Cu concentration (3.5 mol/L), whereas at a Se concentration around 1.0 mol/L, the NY QS was less stringent than the other QSs (P ϭ 0.0009) ( Table 2 ).
The frequencies of unacceptable results [Abs(z score) Ͼ2], according to QS and target concentration, are indicated in Table 3 . Proposed minimal QSs for Cu and Zn based on human biological variability are less stringent than those used by BE and UK TE-EQASs, whereas those used by IT, NY, CA, and FR TE-EQASs lead to similar results when concentrations are within the reference range or higher. When the target concentrations were low, the QS used by NY TE-EQAS tended to be the most stringent for Cu, whereas for Zn the most stringent were those used by CA and FR TE-EQASs. Achieving acceptable performance was easier for Cu than for Zn. For Cu, 43% to 97% (mean 85%) of the participants were within the acceptable range [Abs(z score) Ͻ2] (Table 3 ) depending on concentration and QS, whereas for Zn, 54% to 87% (mean 80%) of the participants were within the acceptable range. For Se, BE, CA, FR, IT, and UK, QSs were similar and tended to be more stringent than the proposed minimal QS based on human biological variation, whereas the QS used by NY TE-EQAS was the least stringent except at low Se concentrations. Using the different QSs, 57% to 92% (mean 73%) of the participants were within the acceptable range [Abs(z score) Ͻ2] (Table 3) . 
, where x i refers to the participant's result and X to the target value.
INFLUENCE OF METHOD ON THE LABORATORY PERFORMANCE AS ASSESSED USING THE PROPOSED MINIMAL QS
The most widely used analytical method for Cu and Zn was FAAS, and for Se, Zeeman background correction ETAAS (Fig. 3) . However, the most popular method for Cu, Zn, and Se in the NY scheme was ICP-MS (41.7% for Cu; 43.7% for Zn; 36.8% for Se). In addition, for Se, 21.0% of the NY scheme's participants used dynamic reaction cell or collision cell ICP-MS. The analytical method significantly influenced Zn (P ϭ 0.05), Cu (P Ͻ 0.0001), and Se (P ϭ 0.003) z scores (Fig. 3) . For Cu, ETAAS with background correction other than Zeeman effect exhibited the poorest performance, with 33% unacceptable z scores [Abs(z score) Ͼ2], whereas this percentage decreased to 8% with ICP-AES/OES and to 20% with the most commonly used FAAS method. For Zn, 11% of Abs(z score) values were Ͼ2 when FAAS, ICP-MS, or ICP-AES/OES were used. This percentage increased to 34% with colorimetric methods. For Se, the percentage of Abs(z score) values Ͼ2 was 20% with ICP-MS and 40% with ETAAS-Z.
Discussion
Reliable measurements are necessary to assist clinicians in the diagnosis of trace element deficiencies and excesses, as well as for monitoring patient follow-up. Participation in external quality assessment schemes or proficiency testing schemes allows laboratories to evaluate the quality of their results. It is also necessary to fulfill the requirements for accreditation (31, 32 ) and, in some jurisdictions, it may be mandated by law (33, 34 ) . Hitherto, definitions of acceptable performance largely have depended on the judgment of scheme organizers. Therefore, from the same set of results, the performance of a laboratory can be considered as adequate in one scheme and inadequate in another, as clearly demonstrated by our results. This observation is well known and has been previously reported (19, 20 ) . This conflict has occurred as the selection of QS can be a difficult task and should take into account both analytical performance and clinical needs (35 ) .
From the analytical point of view, the comparison of equations relating participant SD or reference laboratory SD to target values with those defining the relationships between the QS and trace element concentrations suggests that, for these 3 elements, the QSs in use by IT, BE, CA, FR, and UK schemes are too stringent, when the current interlaboratory analytical precision is taken into account. In addition, achieving acceptable performance was easier for Cu than for Zn, probably owing to the difficulties encountered for zinc determination, especially contamination, which is considered only by the NY QS.
For clinical purposes, the method proposed by Fraser (24 ) for the calculation of QS may afford a useful and objective way to assess laboratory performance. However, it suffers from 2 limitations. First, biological variability is rarely reported in pathological states. As test performance depends on concentration, QS derived exclusively from the healthy population could be insufficient. This is obvious at low concentrations (19 ) . Second, the intra-and interindividual biological variability of the analyte of interest must be evaluated with confidence. Reports dealing with intra-and interindividual variability show discrepant results (36 -39 ) . Ricos et al. (40 ) evaluated the desirable QS for Cu, Zn, and Se and found 12%, 11%, and 14.5% in plasma and 8%, 13.5%, and 14% in serum, respectively. Taking into account more recent reports of inter-and intraindividual variability for Cu, Zn, and Se, the desirable QS obtained in the present work was evaluated at 8% for Cu and Se and 10% for Zn in both serum and plasma. Compared with the current typical analytical performance of laboratories, these desirable QS are unattainable by a large number of participants, especially for Se, but they are also unattainable by reference lab- oratories. Consequently, we proposed using the minimal QS, which is generally slightly less stringent than those currently in use although they do not drastically change the performance evaluation in the different schemes. Nevertheless, desirable QS could be used as an analytical goal. In addition to analytical and clinical needs, the majority of scheme participants must exhibit acceptable results, particularly in sectors where acceptable performance is required for laboratory licensing. At the same time, an objective of external quality assessment is to promote continuous improvement in participant performance, and therefore the QS must not be too large as to give an impression that all is well and not to offer a stimulus toward improvement. The comparison of the participant and reference laboratory precision indicates a huge gap for Se, confirming the expertise of the latter and consequently the possibility of performance improvement by the former. This statement was also true for Cu but to a lesser extent.
Unexpectedly, it was not the case for Zn. These observations suggest a high level of expertise of the Cu and Zn TE-EQAS participants and consequently a weaker potential for performance improvement. Based on the results of our analysis, TE-EQAS organizers may implement slightly different QS for Cu, Zn, and Se in serum or plasma depending on local circumstances (regulatory requirements, participant expertise). The analytical method used, or perhaps its different implementation by various laboratories, is a complicating factor for evaluating performance, as confirmed by our results. Better performances were observed with ICP-OES for Cu and ICP-MS for Se. TE-EQAS organizers are responsible for informing their participants on the limitations of an analytical method and for promoting recommendations for the improvement of analytical performance, as suggested by the International Union of Pure and Applied Chemistry (IUPAC) (30 ) .
Taken as a whole, the proposed minimal QS represent a first step for harmonization of practice among the schemes. The biological view suggests the use of the more stringent desirable QS as a goal standard, whereas the participant results argue for the use of the less-stringent minimal QS. Other issues of TE-EQAS must also urgently be harmonized, such as the determination of target values and elimination of outliers, but also the concentration ranges of delivered samples and the number of duplicate samples per year. It will be equally important to achieve more consistency among schemes in the methods used for the preparation and control (stability and homogeneity) of delivered samples, as well as the measures taken against poor performers. 
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